JP2004500117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500117A5 JP2004500117A5 JP2001572526A JP2001572526A JP2004500117A5 JP 2004500117 A5 JP2004500117 A5 JP 2004500117A5 JP 2001572526 A JP2001572526 A JP 2001572526A JP 2001572526 A JP2001572526 A JP 2001572526A JP 2004500117 A5 JP2004500117 A5 JP 2004500117A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- nucleic acid
- acid molecule
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 239000003814 drug Substances 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 108010035597 sphingosine kinase Proteins 0.000 description 8
- 239000000523 sample Substances 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100027662 Sphingosine kinase 2 Human genes 0.000 description 2
- 101710156532 Sphingosine kinase 2 Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19431800P | 2000-04-03 | 2000-04-03 | |
| US09/817,676 US6800470B2 (en) | 2000-04-03 | 2001-03-26 | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| PCT/US2001/009664 WO2001074837A1 (en) | 2000-04-03 | 2001-03-26 | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004500117A JP2004500117A (ja) | 2004-01-08 |
| JP2004500117A5 true JP2004500117A5 (https=) | 2007-12-13 |
| JP4584525B2 JP4584525B2 (ja) | 2010-11-24 |
Family
ID=26889896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572526A Expired - Fee Related JP4584525B2 (ja) | 2000-04-03 | 2001-03-26 | 哺乳類スフィンゴシンキナーゼタイプ２アイソフォーム、そのクローニング、発現及び使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6800470B2 (https=) |
| JP (1) | JP4584525B2 (https=) |
| KR (1) | KR20020093017A (https=) |
| AU (1) | AU5100201A (https=) |
| CA (1) | CA2404965A1 (https=) |
| DK (1) | DK1268509T3 (https=) |
| HU (1) | HUP0301691A3 (https=) |
| MX (1) | MXPA02009781A (https=) |
| WO (1) | WO2001074837A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001074837A1 (en) * | 2000-04-03 | 2001-10-11 | Sankyo Company, Limited | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| AUPQ744700A0 (en) * | 2000-05-11 | 2000-06-01 | Medvet Science Pty. Ltd. | A method of treatment and agents useful for same |
| US20030157082A1 (en) * | 2002-01-31 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules |
| US20060205688A1 (en) * | 2002-10-14 | 2006-09-14 | Medvet Science Pty. Ltd. | Method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase |
| WO2004061107A1 (ja) * | 2002-12-27 | 2004-07-22 | The New Industry Research Organization | スフィンゴシンキナーゼ２を利用した細胞増殖抑制剤、その核移行シグナルを持つ融合タンパク質の作製方法、及び薬剤候補物質のスクリーニング方法、並びにスクリーニングキット |
| US8314151B2 (en) | 2008-04-29 | 2012-11-20 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, and processes for using same |
| US8372888B2 (en) * | 2008-04-29 | 2013-02-12 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, compositions and processes for using same |
| WO2018237379A2 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374616A (en) * | 1991-10-18 | 1994-12-20 | Georgetown University | Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor |
| WO1999061581A2 (en) * | 1998-05-26 | 1999-12-02 | Office Of The Dean Of Research And Graduate Education | Sphingosine kinase, cloning, expression and methods of use |
| EP1257637A2 (en) * | 2000-02-14 | 2002-11-20 | Curagen Corporation | Sphingosine kinases |
| WO2001074837A1 (en) * | 2000-04-03 | 2001-10-11 | Sankyo Company, Limited | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
-
2001
- 2001-03-26 WO PCT/US2001/009664 patent/WO2001074837A1/en not_active Ceased
- 2001-03-26 HU HU0301691A patent/HUP0301691A3/hu unknown
- 2001-03-26 MX MXPA02009781A patent/MXPA02009781A/es unknown
- 2001-03-26 CA CA002404965A patent/CA2404965A1/en not_active Abandoned
- 2001-03-26 DK DK01924340.1T patent/DK1268509T3/da active
- 2001-03-26 US US09/817,676 patent/US6800470B2/en not_active Expired - Fee Related
- 2001-03-26 AU AU5100201A patent/AU5100201A/xx active Pending
- 2001-03-26 JP JP2001572526A patent/JP4584525B2/ja not_active Expired - Fee Related
- 2001-03-26 KR KR1020027013149A patent/KR20020093017A/ko not_active Withdrawn
-
2004
- 2004-04-22 US US10/830,677 patent/US7419814B2/en not_active Expired - Fee Related
-
2007
- 2007-08-14 US US11/891,964 patent/US7803595B2/en not_active Expired - Fee Related
-
2010
- 2010-07-27 US US12/804,664 patent/US8263349B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2080812A1 (en) | Compositions and methods of detecting post-stop peptides | |
| JP2005503127A (ja) | エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド | |
| US7041794B2 (en) | Polynucleotides and polypeptides of the erythropoietin gene | |
| JP4969638B2 (ja) | 単球由来核酸および関連する組成物ならびに方法 | |
| JP2006518186A5 (https=) | ||
| JP2004500117A5 (https=) | ||
| JP2005537007A5 (https=) | ||
| CA2408847A1 (en) | Cng3b: a novel cyclic nucleotide-gated cation channel | |
| JP2004290197A5 (https=) | ||
| EP1462527A1 (en) | Novel markers for inflammatory bowel disease | |
| JP2003000281A (ja) | Ｉｆｎアルファー２遺伝子の新規ポリヌクレオチド及びポリペプチド | |
| JP2004500009A5 (https=) | ||
| KR20010112861A (ko) | 만성 류마티스성 관절염질환 유전자와 만성 류마티스성관절염의 진단방법 | |
| WO2002072761A9 (en) | Polypeptides interactive with bcl-x¿l? | |
| CA2418848A1 (en) | Cng2b: a novel human cyclic nucleotide-gated ion channel | |
| KR102653463B1 (ko) | 매트릭스 메탈로프로테이나제 13 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단 마커 | |
| CA2478016A1 (en) | Presynaptic protein p120 | |
| KR100764844B1 (ko) | Ｈｂｖ ｘ 항원을 이용한 ｂ형 간염에서 유래된 간질환진단용 키트 | |
| JP2007060966A (ja) | Ｄｎａ標準物質 | |
| Degl'Innocenti et al. | ACYP1 gene possesses two alternative splicing forms that induce apoptosis | |
| EP0996716A1 (en) | Zggbp1,novel peptides related to bipolar affective disorder type 1, sequences and uses thereof | |
| CN121175436A (zh) | 用压电式机械敏感离子通道组分1(piezo1)激动剂治疗静脉曲张 | |
| JP2005507633A5 (https=) | ||
| Augustyńska et al. | Assessment of the frequency of the transforming growth factor beta-1 sequence polymorphisms in patients with alcohol dependence syndrome. | |
| US20030119044A1 (en) | Tumor suppressors associated with human chromosome 21q22 |